Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 104 entries
Sorted by: Best Match Show Resources per page
Annotated patent selections.

Expert opinion on therapeutic patents

Norman P.
PMID: 20141504
Expert Opin Ther Pat. 2005 Jun;15(6):715-39. doi: 10.1517/13543776.15.6.715.

No abstract available.

Cite
Norman P. Annotated patent selections. Expert Opin Ther Pat. 2005;15(6):715-39doi: 10.1517/13543776.15.6.715.
Norman, P. (2005). Annotated patent selections. Expert opinion on therapeutic patents, 15(6), 715-39. https://doi.org/10.1517/13543776.15.6.715
Norman, P. "Annotated patent selections." Expert opinion on therapeutic patents vol. 15,6 (2005): 715-39. doi: https://doi.org/10.1517/13543776.15.6.715
Norman P. Annotated patent selections. Expert Opin Ther Pat. 2005 Jun;15(6):715-39. doi: 10.1517/13543776.15.6.715. PMID: 20141504.
Copy Download .nbib Format: NLM
The sulfamide motif in the design of enzyme inhibitors.

Expert opinion on therapeutic patents

Winum JY, Scozzafava A, Montero JL, Supuran CT.
PMID: 20141508
Expert Opin Ther Pat. 2006 Jan;16(1):27-47. doi: 10.1517/13543776.16.1.27.

The sulfamide moiety, similarly to the structurally related sulfonamide and sulfamate ones, is widely employed in medicinal chemistry for the design of biologically active compounds. Amongst the enzymes for which sulfamide-based inhibitors were designed are the carbonic anhydrases (CAs),...

Cite
Winum JY, Scozzafava A, Montero JL, et al. The sulfamide motif in the design of enzyme inhibitors. Expert Opin Ther Pat. 2006;16(1):27-47doi: 10.1517/13543776.16.1.27.
Winum, J. Y., Scozzafava, A., Montero, J. L., & Supuran, C. T. (2006). The sulfamide motif in the design of enzyme inhibitors. Expert opinion on therapeutic patents, 16(1), 27-47. https://doi.org/10.1517/13543776.16.1.27
Winum, Jean-Yves, et al. "The sulfamide motif in the design of enzyme inhibitors." Expert opinion on therapeutic patents vol. 16,1 (2006): 27-47. doi: https://doi.org/10.1517/13543776.16.1.27
Winum JY, Scozzafava A, Montero JL, Supuran CT. The sulfamide motif in the design of enzyme inhibitors. Expert Opin Ther Pat. 2006 Jan;16(1):27-47. doi: 10.1517/13543776.16.1.27. PMID: 20141508.
Copy Download .nbib Format: NLM
Natural, synthetic and semisynthetic glycolipid inhibitors of glioma growth.

Expert opinion on therapeutic patents

Nieto-Sampedro M, Doncel-Pérez E, Fernández-Mayoralas A.
PMID: 21793650
Expert Opin Ther Pat. 2004 Apr;14(4):487-97. doi: 10.1517/13543776.14.4.487.

Neurostatin, a natural glycosphingolipid inhibitor of astroblast and astrocytoma division, present in mammalian brain, is the modified ganglioside O-acetylated GD1b. It is cytostatic for rat astroblasts, C6 glioma cells and various human astrocytoma lines grades III and IV, with...

Cite
Nieto-Sampedro M, Doncel-Pérez E, Fernández-Mayoralas A. Natural, synthetic and semisynthetic glycolipid inhibitors of glioma growth. Expert Opin Ther Pat. 2004;14(4):487-97doi: 10.1517/13543776.14.4.487.
Nieto-Sampedro, M., Doncel-Pérez, E., & Fernández-Mayoralas, A. (2004). Natural, synthetic and semisynthetic glycolipid inhibitors of glioma growth. Expert opinion on therapeutic patents, 14(4), 487-97. https://doi.org/10.1517/13543776.14.4.487
Nieto-Sampedro, Manuel, et al. "Natural, synthetic and semisynthetic glycolipid inhibitors of glioma growth." Expert opinion on therapeutic patents vol. 14,4 (2004): 487-97. doi: https://doi.org/10.1517/13543776.14.4.487
Nieto-Sampedro M, Doncel-Pérez E, Fernández-Mayoralas A. Natural, synthetic and semisynthetic glycolipid inhibitors of glioma growth. Expert Opin Ther Pat. 2004 Apr;14(4):487-97. doi: 10.1517/13543776.14.4.487. PMID: 21793650.
Copy Download .nbib Format: NLM
Corticotropin-releasing factor receptor antagonists.

Expert opinion on therapeutic patents

Gilligan PJ.
PMID: 20144054
Expert Opin Ther Pat. 2006 Jul;16(7):913-24. doi: 10.1517/13543776.16.7.913.

Corticotropin-releasing factor (CRF) coordinates the neural, endocrine and immune responses of the body to stress. Therefore, CRF receptors are important targets for the design of drugs for depression, anxiety and stress-related disorders. Several laboratories have published extensive preclinical and...

Cite
Gilligan PJ. Corticotropin-releasing factor receptor antagonists. Expert Opin Ther Pat. 2006;16(7):913-24doi: 10.1517/13543776.16.7.913.
Gilligan, P. J. (2006). Corticotropin-releasing factor receptor antagonists. Expert opinion on therapeutic patents, 16(7), 913-24. https://doi.org/10.1517/13543776.16.7.913
Gilligan, Paul J. "Corticotropin-releasing factor receptor antagonists." Expert opinion on therapeutic patents vol. 16,7 (2006): 913-24. doi: https://doi.org/10.1517/13543776.16.7.913
Gilligan PJ. Corticotropin-releasing factor receptor antagonists. Expert Opin Ther Pat. 2006 Jul;16(7):913-24. doi: 10.1517/13543776.16.7.913. PMID: 20144054.
Copy Download .nbib Format: NLM
Adenovirus-vectored vaccines.

Expert opinion on therapeutic patents

Chawla T, Khanna N, Swaminathan S.
PMID: 20144086
Expert Opin Ther Pat. 2008 Mar;18(3):293-307. doi: 10.1517/13543776.18.3.293.

BACKGROUND: Engineered adenoviruses are being increasingly explored as immunoprophylactic or immunotherapeutic vaccine vectors. Encouraging data from preclinical studies using human adenovirus vectors carrying different antigen genes have resulted in many currently ongoing clinical trials.OBJECTIVE: The article seeks to review...

Cite
Chawla T, Khanna N, Swaminathan S. Adenovirus-vectored vaccines. Expert Opin Ther Pat. 2008;18(3):293-307doi: 10.1517/13543776.18.3.293.
Chawla, T., Khanna, N., & Swaminathan, S. (2008). Adenovirus-vectored vaccines. Expert opinion on therapeutic patents, 18(3), 293-307. https://doi.org/10.1517/13543776.18.3.293
Chawla, Tanu, et al. "Adenovirus-vectored vaccines." Expert opinion on therapeutic patents vol. 18,3 (2008): 293-307. doi: https://doi.org/10.1517/13543776.18.3.293
Chawla T, Khanna N, Swaminathan S. Adenovirus-vectored vaccines. Expert Opin Ther Pat. 2008 Mar;18(3):293-307. doi: 10.1517/13543776.18.3.293. PMID: 20144086.
Copy Download .nbib Format: NLM
Dihydrofolate reductase inhibitors: developments in antiparasitic chemotherapy.

Expert opinion on therapeutic patents

Bolstad DB, Bolstad ES, Wright DL, Anderson AC.
PMID: 20553119
Expert Opin Ther Pat. 2008 Feb;18(2):143-57. doi: 10.1517/13543776.18.2.143.

BACKGROUND: Infections caused by parasitic protozoa present a growing health concern, particularly in developing parts of the world. Although malaria is clearly the most well-known and deadly of these diseases, infections caused by other parasites, such as Toxoplasma, Cryptosporidia...

Cite
Bolstad DB, Bolstad ES, Wright DL, et al. Dihydrofolate reductase inhibitors: developments in antiparasitic chemotherapy. Expert Opin Ther Pat. 2008;18(2):143-57doi: 10.1517/13543776.18.2.143.
Bolstad, D. B., Bolstad, E. S., Wright, D. L., & Anderson, A. C. (2008). Dihydrofolate reductase inhibitors: developments in antiparasitic chemotherapy. Expert opinion on therapeutic patents, 18(2), 143-57. https://doi.org/10.1517/13543776.18.2.143
Bolstad, David B, et al. "Dihydrofolate reductase inhibitors: developments in antiparasitic chemotherapy." Expert opinion on therapeutic patents vol. 18,2 (2008): 143-57. doi: https://doi.org/10.1517/13543776.18.2.143
Bolstad DB, Bolstad ES, Wright DL, Anderson AC. Dihydrofolate reductase inhibitors: developments in antiparasitic chemotherapy. Expert Opin Ther Pat. 2008 Feb;18(2):143-57. doi: 10.1517/13543776.18.2.143. PMID: 20553119.
Copy Download .nbib Format: NLM
Inventors and their attorneys must beware of their actions before the US Patent and Trademark Office.

Expert opinion on therapeutic patents

Warburg R, Nguyen L.
PMID: 21793649
Expert Opin Ther Pat. 2004 Apr;14(4):453-6. doi: 10.1517/13543776.14.4.453.

Inventors and their legal representative have a duty to disclose all material information of which they are aware to the United States Patent and Trademark Office (USPTO). Breach of this duty, combined with an intent to deceive the USPTO,...

Cite
Warburg R, Nguyen L. Inventors and their attorneys must beware of their actions before the US Patent and Trademark Office. Expert Opin Ther Pat. 2004;14(4):453-6doi: 10.1517/13543776.14.4.453.
Warburg, R., & Nguyen, L. (2004). Inventors and their attorneys must beware of their actions before the US Patent and Trademark Office. Expert opinion on therapeutic patents, 14(4), 453-6. https://doi.org/10.1517/13543776.14.4.453
Warburg, Richard, and Nguyen, Lauren. "Inventors and their attorneys must beware of their actions before the US Patent and Trademark Office." Expert opinion on therapeutic patents vol. 14,4 (2004): 453-6. doi: https://doi.org/10.1517/13543776.14.4.453
Warburg R, Nguyen L. Inventors and their attorneys must beware of their actions before the US Patent and Trademark Office. Expert Opin Ther Pat. 2004 Apr;14(4):453-6. doi: 10.1517/13543776.14.4.453. PMID: 21793649.
Copy Download .nbib Format: NLM
Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021).

Expert opinion on therapeutic patents

Banerjee P, Mandhare A, Bagalkote V.
PMID: 34872430
Expert Opin Ther Pat. 2022 Jan 05;1-47. doi: 10.1080/13543776.2022.2012150. Epub 2022 Jan 05.

INTRODUCTION: Marine natural products have aided as rich sources of new bioactive agents. The multiplicity of marine habitations and exclusive ecological conditions of the sea offer mostly unexploited sources of unique biological and chemical entities. In continuation with the...

Cite
Banerjee P, Mandhare A, Bagalkote V. Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021). Expert Opin Ther Pat. 2022;1-47doi: 10.1080/13543776.2022.2012150.
Banerjee, P., Mandhare, A., & Bagalkote, V. (2022). Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021). Expert opinion on therapeutic patents, 1-47. https://doi.org/10.1080/13543776.2022.2012150
Banerjee, Paromita, et al. "Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021)." Expert opinion on therapeutic patents vol. (2022): 1-47. doi: https://doi.org/10.1080/13543776.2022.2012150
Banerjee P, Mandhare A, Bagalkote V. Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021). Expert Opin Ther Pat. 2022 Jan 05;1-47. doi: 10.1080/13543776.2022.2012150. Epub 2022 Jan 05. PMID: 34872430.
Copy Download .nbib Format: NLM
[No title available]

Expert opinion on therapeutic patents

Marichev KO, Patil SA, Patil SA, Heras Martinez HM, Bugarin A.
PMID: 34365884
Expert Opin Ther Pat. 2021 Aug 18;1-15. doi: 10.1080/13543776.2021.1965992. Epub 2021 Aug 18.

INTRODUCTION: Besides the well-established catalytic, synthetic and materials related applications of N-heterocyclic carbene (NHC) metal complexes, their use as therapeutics deserves a special attention. Many literature reports indicate that their bioactivity is superior to other organometallic compounds. The main...

Cite
Marichev KO, Patil SA, Patil SA, et al. . Expert Opin Ther Pat. 2021;1-15doi: 10.1080/13543776.2021.1965992.
Marichev, K. O., Patil, S. A., Patil, S. A., Heras Martinez, H. M., & Bugarin, A. (2021). . Expert opinion on therapeutic patents, 1-15. https://doi.org/10.1080/13543776.2021.1965992
Marichev, Kostiantyn O, et al. "." Expert opinion on therapeutic patents vol. (2021): 1-15. doi: https://doi.org/10.1080/13543776.2021.1965992
Marichev KO, Patil SA, Patil SA, Heras Martinez HM, Bugarin A. . Expert Opin Ther Pat. 2021 Aug 18;1-15. doi: 10.1080/13543776.2021.1965992. Epub 2021 Aug 18. PMID: 34365884.
Copy Download .nbib Format: NLM
Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).

Expert opinion on therapeutic patents

Gonzalez Lopez de Turiso F, Guckian K.
PMID: 35001782
Expert Opin Ther Pat. 2022 Jan 10; doi: 10.1080/13543776.2022.2026927. Epub 2022 Jan 10.

INTRODUCTION: Tyrosine kinase 2 (TYK2) is a member of the JAK family class of kinases that is responsible for mediating the immune response to IL-12, IL-23, and IFNα. The therapeutic value of targeting this pathway in autoimmune diseases is...

Cite
Gonzalez Lopez de Turiso F, Guckian K. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021). Expert Opin Ther Pat. 2022;doi: 10.1080/13543776.2022.2026927.
Gonzalez Lopez de Turiso, F., & Guckian, K. (2022). Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021). Expert opinion on therapeutic patents, . https://doi.org/10.1080/13543776.2022.2026927
Gonzalez Lopez de Turiso, Felix, and Guckian, Kevin. "Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021)." Expert opinion on therapeutic patents vol. (2022). doi: https://doi.org/10.1080/13543776.2022.2026927
Gonzalez Lopez de Turiso F, Guckian K. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021). Expert Opin Ther Pat. 2022 Jan 10; doi: 10.1080/13543776.2022.2026927. Epub 2022 Jan 10. PMID: 35001782.
Copy Download .nbib Format: NLM
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).

Expert opinion on therapeutic patents

Scott JS, Barlaam B.
PMID: 34763600
Expert Opin Ther Pat. 2021 Nov 11; doi: 10.1080/13543776.2022.2006185. Epub 2021 Nov 11.

INTRODUCTION: The estrogen receptor (ER) is a clinically validated oncology target with a pivotal role in hormonally driven breast cancer, the most prevalent form of female cancer. Current treatments which directly modulate ER include antagonists (SERMs), such as tamoxifen,...

Cite
Scott JS, Barlaam B. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present). Expert Opin Ther Pat. 2021;doi: 10.1080/13543776.2022.2006185.
Scott, J. S., & Barlaam, B. (2021). Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present). Expert opinion on therapeutic patents, . https://doi.org/10.1080/13543776.2022.2006185
Scott, James S, and Barlaam, Bernard. "Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present)." Expert opinion on therapeutic patents vol. (2021). doi: https://doi.org/10.1080/13543776.2022.2006185
Scott JS, Barlaam B. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present). Expert Opin Ther Pat. 2021 Nov 11; doi: 10.1080/13543776.2022.2006185. Epub 2021 Nov 11. PMID: 34763600.
Copy Download .nbib Format: NLM
An updated patent review of small-molecule c-Met kinase inhibitors (2018-present).

Expert opinion on therapeutic patents

Chu C, Rao Z, Pan Q, Zhu W.
PMID: 34791961
Expert Opin Ther Pat. 2021 Nov 29;1-20. doi: 10.1080/13543776.2022.2008356. Epub 2021 Nov 29.

INTRODUCTION: c-Met tyrosine kinase receptor is a high-affinity ligand of hepatocyte growth factor (HGF). c-Met is widely expressed in a variety of normal human tissues, but shows abnormally high expression, amplification or mutation in tumour tissues such as lung,...

Cite
Chu C, Rao Z, Pan Q, et al. An updated patent review of small-molecule c-Met kinase inhibitors (2018-present). Expert Opin Ther Pat. 2021;1-20doi: 10.1080/13543776.2022.2008356.
Chu, C., Rao, Z., Pan, Q., & Zhu, W. (2021). An updated patent review of small-molecule c-Met kinase inhibitors (2018-present). Expert opinion on therapeutic patents, 1-20. https://doi.org/10.1080/13543776.2022.2008356
Chu, Cilong, et al. "An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)." Expert opinion on therapeutic patents vol. (2021): 1-20. doi: https://doi.org/10.1080/13543776.2022.2008356
Chu C, Rao Z, Pan Q, Zhu W. An updated patent review of small-molecule c-Met kinase inhibitors (2018-present). Expert Opin Ther Pat. 2021 Nov 29;1-20. doi: 10.1080/13543776.2022.2008356. Epub 2021 Nov 29. PMID: 34791961.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 104 entries